Results 41 to 50 of about 558,869 (280)

Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy

International Journal of Molecular Sciences, 2019
The ever-increasing incidence of drug-resistant Mycobacterium tuberculosis infections has invigorated the focus on the discovery and development of novel treatment options.
Eveline Torfs, Tatiana Piller, Paul Cos   +2 more
exaly   +2 more sources

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? [PDF]

Diabetes Res Clin Pract, 2020
: 2020 Elsevier B.V. All rights reserved. Most of the expert consensus to date have suggested physician Jean Sterne, in the treatment of diabetes in 1957 avoiding metformin in patients with diabetes and coronavirus disease-19 (COVID-19), due to an ...
Singh AK, Singh R.
europepmc   +2 more sources

Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. [PDF]

Int J Pharm, 2022
Khoza LJ, Kumar P, Dube A, Demana PH, Choonara YE.   +4 more
europepmc   +2 more sources

Host-directed therapies for tackling multi-drug resistant tuberculosis : learning from the pasteur-bechamp debates [PDF]

, 2015
Tuberculosis remains a global emergency causing an estimated 1.5 million deaths annually. For several decades the major focus of tuberculosis treatment has been on antibiotic development targeting Mycobacterium tuberculosis.
Abdulla, S, Cardona, P-J, Grobusch, MP, Mboko, L, Gant, V, Mayosi, B, Zumla, A, Mandansein, R, Reither, K, Mwaba, P, Nyirenda, T, Garcia-Basteiro, AL, Bates, M, Ippolito, G, Munderi, P, Singh, N, Schito, M, Dieye, TN, Diarra, B, Kaleebu, P, Aseffa, A, Tientcheu, L, Corrah, T, Mulenga, M, Parida, S, Kaufmann, SHE, Macete, E, Noursadeghi, M, Petersen, E, Vilaplana, C, Rakotosamimanana, N, Yeboah-Manu, D, Rustomjee, R, Wejse, C, Martinson, N, Elkington, P, McHugh, TD, Oliver, M, Russell, JBW, Host-Directed Therapies Network Consortium,, Wallis, RS, Sanne, I, Chakaya, J, Bonnet, M, Antonio, M, Padayatchi, N, Sheikh, A, Maeurer, Markus, Host-Directed Therapies Network (HDT-NET) Consortium, ., Rasolofo, V, Kibiki, G, Zumla, A., Maeurer, M, Churchyard, G, Maiga, A, Aklillu, E, Ramjee, G, Mfinanga, E, Hoelscher, M, Steyn, AJC, Ntoumi, F, Edwards, S, Kapata, N, Gagneux, S, Menendez, C, Zumla, Alimuddin, Maeurer, M., Craig, G, Mfinanga, S, Wilkinson, RJ   +69 more
core   +7 more sources

Host-Directed Antiviral Therapy [PDF]

Clinical Microbiology Reviews, 2020
Antiviral drugs have traditionally been developed by directly targeting essential viral components. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Recent genome-wide approaches, such as those employing small interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats (CRISPR) or those ...
Naveen Kumar, Shalini Sharma, Ram Kumar, Bhupendra N. Tripathi, Sanjay Barua, Hinh Ly, Barry T. Rouse   +6 more
openaire   +2 more sources

Host-Directed Therapies for Cutaneous Leishmaniasis [PDF]

Frontiers in Immunology, 2021
Cutaneous leishmaniasis exhibits a wide spectrum of clinical presentations from self-resolving infections to severe chronic disease. Anti-parasitic drugs are often ineffective in the most severe forms of the disease, and in some cases the magnitude of the disease can result from an uncontrolled inflammatory response rather than unrestrained parasite ...
Fernanda O. Novais, Camila Farias Amorim, Phillip Scott   +2 more
openaire   +3 more sources

mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis [PDF]

Infection and Immunity
Robin H. G. A. van den Biggelaar, Tom H. M. Ottenhoff   +1 more
doaj   +2 more sources

Host Directed Therapies for Tuberculous Meningitis [PDF]

Wellcome Open Research, 2020
A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality.
Davis, Angharad G., Donovan, Joseph, Bremer, Marise, Van Toorn, Ronald, Schoeman, Johan, Dadabhoy, Ariba, Lai, Rachel P. J., Cresswell, Fiona V., Boulware, David R., Wilkinson, Robert J., Thuong, Nguyen Thuy Thuong, Thwaites, Guy E., Bahr, Nathan C., Tuberculous Meningitis International Research Consortium   +13 more
openaire   +5 more sources

Immunomodulatory effects of cysteamine and its potential use as a host-directed therapy for tuberculosis. [PDF]

Front Immunol
Najafi-Fard S, Farroni C, Petrone L, Altera AMG, Salmi A, Vanini V, Cuzzi G, Alonzi T, Nicastri E, Gualano G, Palmieri F, Piacentini M, Goletti D.   +12 more
europepmc   +2 more sources

Host-directed therapies for COVID-19

Current Opinion in Pulmonary Medicine, 2021
Purpose of review Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management.
Maeurer, M, Ramalho, R, Wang, F-S, Zumla, A   +3 more
openaire   +4 more sources